Trialbee is set to unveil a new multichannel approach to global patient recruitment, Trialbee Honey Omnichannel, which enables multiple recruitment sources tracking.
The latest solution provides a simplified patient journey to sponsors and contract research organisations (CROs) into the study, with consistent messaging and pre-qualification.
This helps minimise the burden of managing referrals at research sites and also provides real-time analytics for all recruitment activities worldwide.
Study teams will also be able to drive better enrolment and diversity outcomes for their clinical trial.
Available in the company’s flagship software as a system (SaaS)-based Trialbee Honey platform, the new offering will be provided with comprehensive, indication-specific international recruitment strategies.
Trialbee CEO Matt Walz said: “Single-tactic recruitment strategies running across disparate and disconnected technology solutions are no longer solving for the increasing recruitment, operational, and staffing challenges facing our industry.
“Our aim is to provide a single platform to channel all recruitment and enrolment activities, which provides a better patient experience, reduces staff time at CROs and research sites, and surfaces real-time data for better decision making.”
The company will introduce Honey Omnichannel with lupus, a complex disease, as the pilot indication for showing the combination of a comprehensive recruitment strategy, a recruitment partner ecosystem, and the advanced tracking platform for patient recruitment.
With Omnichannel, those impacted by this disease are aware of clinical trials prior to making a decision.
Trialbee combines recruitment and enrolment strategies, technology, and services for a new platform-based model for patient recruitment.
This year, TrialBee announced a partnership with Ergomed to act as the patient recruitment platform for the latter’s newly unveiled Rare Disease Innovation Center.